Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW

AbbVie reported that its drug Rinvoq (upadacitinib) maintains Crohn's endoscopic remission rates between 47.1% and 64.2% at week 144, while Skyrizi (risankizumab) sustains ulcerative colitis endoscopic remission rates of 38.8% to 53.5% at week 96. The company highlighted 20 scientific presentations demonstrating its leadership in inflammatory bowel disease (IBD) research. Additionally, new data on the investigational dual-targeting therapy ABBV-466 for moderate-to-severe Crohn's disease will be presented.